ACS BrightEdge

ACS BrightEdge is the innovation and impact investment arm of the American Cancer Society (ACS), dedicated to accelerating the commercialization of patient-centric innovations across the cancer continuum. By investing in early-stage companies developing cutting-edge cancer-focused therapeutics, diagnostics, devices, and technologies, BrightEdge aims to reduce cancer mortality, end pain and suffering, and advance health equity.

The fund operates at the intersection of investment, innovation, and impact, leveraging ACS's extensive legacy in cancer research and patient support to identify and invest in actionable and scalable solutions. BrightEdge's portfolio comprises companies working on solutions across the cancer-patient continuum, from prevention and disease awareness to cutting-edge diagnostics, treatments, and solutions to patient access.

Investment returns from the BrightEdge portfolio are reinvested in both the fund and ACS's life-saving programs in research, access, and health equity. Since its formation in 2019, BrightEdge has invested a total of $43 million in 21 companies focused on developing innovations to address critical needs along the cancer care continuum.

BrightEdge's investment decisions and innovation programming are guided by the mission priorities of ACS and seek to achieve mission-driven social impact through its proprietary Cancer Impact Investment Framework (CIIF). This framework evaluates and measures the actual and potential impact of investments in accordance with ACS's mission-driven priorities.

By strategically investing in entrepreneurial early-stage companies, BrightEdge aims to catalyze impact innovation and generate financial returns that can be reinvested to sustain ACS's lifesaving work for decades to come.